Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
2.500
+0.020 (0.81%)
At close: Jan 14, 2025, 4:00 PM
2.510
+0.010 (0.40%)
After-hours: Jan 14, 2025, 4:41 PM EST
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $4.35M in the quarter ending September 30, 2024, a decrease of -53.18%. This brings the company's revenue in the last twelve months to $27.08M, up 26.35% year-over-year. In the year 2023, Aclaris Therapeutics had annual revenue of $31.25M with 5.03% growth.
Revenue (ttm)
$27.08M
Revenue Growth
+26.35%
P/S Ratio
6.57
Revenue / Employee
$297,571
Employees
91
Market Cap
267.47M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
ACRS News
- 8 days ago - Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy - Benzinga
- 7 weeks ago - Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 2 months ago - Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Benzinga
- 2 months ago - Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - PRNewsWire
- 2 months ago - Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics Announces $80 Million Private Placement - GlobeNewsWire
- 4 months ago - Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis - GlobeNewsWire